Effects of echinocandins on cytokine/chemokine production by human monocytes activated by infection with Candida glabrata or by lipopolysaccharide

Diagnostic Microbiology and Infectious Disease

Volumn 72, Issue 3, 2012, Pages 226-233

  Baltch, Aldona L ^a,b   Lawrence, David A ^c   Ritz, William J ^a,b   Andersen, Nancy J ^c   Bopp, Lawrence H ^a,b,d   Michelsen, Phyllis B ^a,b   Carlyn, Cynthia J ^a,b   Smith, Raymond P ^a,b  

^a STRATTON VA MEDICAL CENTER   (United States)

^b ALBANY MEDICAL COLLEGE   (United States)

^c WADSWORTH CENTER   (United States)

^d Center for Agriculture and Natural Resources   (United States)

Author keywords

Antifungal drugs; Candida glabrata; Cytokines chemokines; Echinocandins; Human monocytes

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; ECHINOCANDIN; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MICAFUNGIN; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA; VORICONAZOLE;

ARTICLE; CANDIDA GLABRATA; CANDIDIASIS; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; FUNGAL STRAIN; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE ACTIVATION; MONOCYTE; NONHUMAN; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDIASIS; CHEMOKINES; CYTOKINES; ECHINOCANDINS; HUMANS; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MACROPHAGES;

EID: 84856593507     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2011.11.004     Document Type: Article

References (49)

1. Baltch A.L., Lawrence D., Ritz W.J., Andersen N., Bopp L., Smith R. Modulation by anidulafungin and voriconazole, singly and in combination, of cytokine production by human monocytes infected with Candida glabrata and by uninfected monocytes. Abstract M-362. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12-15, 2009 2009, 340. San Francisco, CA.
2. Baltch A.L., Bopp L.H., Smith R.P., Ritz W.J., Carlyn C.J., Michelsen P.B. Effects of voriconazole, granulocyte-macrophage colony-stimulating factor, and interferon γ on intracellular fluconazole-resistant Candida glabrata and Candida krusei in human monocyte-derived macrophages. Diagn. Microbiol. Infect. Dis. 2005, 52:299-304.
3. Barcia-Macay M., Seral C., Mingeot-Leclercq M.P., Tulkens P.M., Van Bambeke F. Pharmacodynamic evaluation of the intracellular activities of antibiotics against THP-1 macrophages. Antimicrob. Agents Chemother. 2006, 50:841-851.
4. Bozza S., Fallarino F., Pitzurra L., Zelante T., Montagnoli C., Bellocchio S., Mosci P., Vacca C., Puccetti P., Romani L. A crucial role for tryptophan catabolism at the host Candida albicans interface. J. Immunol. 2005, 174:2910-2918.
5. Brown G.D., Gordon S. Immune recognition of fungal β-glucans. Cell. Microbiol. 2005, 7:471-479.
6. Brown G.D., Gordon S. Fungal β-glucans and mammalian immunity. Immunity 2003, 19:311-315.
7. Cappelletty D., Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007, 27:369-388.
8. Chakrabarti A., Chen A.W., Varner J.D. A review of the mammalian unfolded protein response. Biotechnol. Bioeng. 2011, 108:2777-2793.
9. Cheng S.C., van de Veerdontk F., Smeekens S., Joosten L.A., van der Meer J.W., Kulberg B.J., Netea M.G. Candida albicans dampens host defense by downregulating IL-17 production. J. Immunol. 2010, 185:2450-2457.
10. Clinical and Laboratory Standards Institute (CLSI) Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard - third edition, M27-A3 2008, CLSI, Wayne, PA.
11. Dale D.C., Boxer L., Liles W.C. The phagocytes: neutrophils and monocytes. Blood 2008, 112:935-945.
12. English B.K., Maryniw E.M., Palati A.J., Meals E.A. Diminished macrophage inflammatory response to Staphylococcus aureus isolates exposed to daptomycin versus vancomycin or oxacillin. Antimicrob. Agents Chemother. 2006, 50:2225-2227.
13. Fidel P.L., Vazquez J.A., Sobel J.D. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin. Microbiol. Rev. 1999, 12:80-96.
14. Frank U., Greiner M., Engels L., Daschner F.D. Effects of caspofungin (MK-0991) and anidulafungin (LY 303366) on phagocytosis, oxidative burst and killing of Candida albicans by human phagocytes. Eur. J. Clin. Microbiol. Infect. Dis. 2004, 23:729-731.
15. Horn D.L., Neofytos D., Anaissie E.J., Fishman J.A., Steinbach W.J., Olyaei A.J., Marr K.A., Pfaller M.A., Chang C.H., Webster K.M. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin. Infect. Dis. 2009, 48:1695-1703.
16. Hotamisligil G.S. Endoplasmic reticulum stress and the inflammatory basis of metabolic disease. Cell 2010, 140:900-917.
17. Johnson M.D., Perfect J.R. Use of antifungal combination therapy: agents, order, and timing. Curr. Fungal Infect. Rep. 2010, 4:87-95.
18. Kanoh S., Rubin B.K. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin. Microbiol. Rev. 2010, 23:590-615.
19. Kellum J.A., Kong L., Fink M.P., Weissell L.A., Yealy D.M., Pinsky M.R., Fine J., Krichevsky A., Delude R.L., Angus D.C. Understanding the inflammatory cytokine response in pneumonia and sepsis. Arch. Int. Med. 2007, 167:1655-1663. for the Gen IMS Investigators.
20. Kinoshita K., Iwasaki H., Uzui H., Ueda T. Candin family antifungal agent micafungin (FK463) modulates the inflammatory cytokine/chemokine production stimulated by lipopolysaccharide in THP-1 cells. Transl. Res. 2006, 148:207-213.
21. Labro M.T. Immunological effects of macrolides. Curr. Opin. Infect. Dis. 1998, 11:681-688.
22. Maródi L., Korchak H.M., Johnston R.B. Mechanisms of host defense against Candida species: I. Phagocytosis by monocytes and monocyte-derived macrophages. J. Immunol. 1991, 146:2783-2789.
23. Maródi L., Forehand J.R., Johnston R.B. Mechanisms of host defense against Candida species: II. Biochemical basis for the killing of Candida by mononuclear phagocytes. J. Immunol. 1991, 146:2790-2794.
24. Mogensen T.H. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 2009, 22:240-273.
25. Mogensen T.H., Paludan S.R., Kilian M., Ostergaard L. Live Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis activate the inflammatory response through Toll-like receptors 2, 4, and 9 in species-specific patterns. J. Leukoc. Biol. 2006, 80:267-277.
26. Netea M.G., Gow N.A., Munro C.A., Bates S., Collins C., Fererda G., Hobson R.P., Bertram G., Hughes H.B., Jansen T., Jacobs L., Buurman E.T., Gijzen K., Williams D.L., Torensma R., McKinnon A., MacCallum D.M., Odds F.C., Van der Meer J.W., Brown A.J., Kullberg B.J. Immune sensing of Candida albicans requires cooperative recognition of mannans and glucans by lectin and Toll-like receptors. J. Clin. Invest. 2006, 116:1642-1650.
27. Orman K.L., English B.K. Effects of antibiotic class on the macrophage inflammatory response to Streptococcus pneumoniae. J. Infect. Dis. 2000, 182:1561-1565.
28. Oxman D.A., Chow J.K., Frendl G., Hadley S., Hershkovitz S., Ireland P., McDermott L.A., Marty F.M., Kontoyiannis D.P., Golan Y. Candidemia associated with decreased in vitro fluconazole susceptibilities: Is Candida speciation predictive of the susceptibility pattern?. J. Antimicrob. Chemother. 2010, 65:1460-1465.
29. Pappas P.G., Kauffman C.A., Andes D., Benjamin D.K., Calandra T.F., Edwards J.E., Filler S.G., Fisher J.F., Kulberg B.J., Ostrosky-Zeichner L., Reboli A.C., Rex J.H., Walsh T.J., Sobel J.D. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Disease Society of America. Clin. Infect. Dis. 2009, 48:503-535.
30. Pfaller M.A., Diekema D.J. Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility. J. Clin. Microbiol. 2002, 40:3551-3557.
31. Pinsky M.R., Vincent J.L., Deviere J., Alegre M., Kahn R.J., Dupont E. Serum cytokine levels in human septic shock: relation to multiple-system organ failure and mortality. Chest 1993, 103:565-575.
32. Pound M.W., Townsend M.L., Drew R.H. Echinocandin pharmacodynamics. J. Antimicrob. Chemother. 2010, 65:1108-1118.
33. Rapp U.K., Kaufmann S.H.E. Glucose-regulated stress proteins and antimicrobial immunity. Trends Microbiol. 2003, 11:519-526.
34. Rath E., Haller D. Inflammation and cellular stress: a mechanistic link between immune-mediated and metabolically driven pathologies. Eur. J. Nutr. 2011, 50:219-233.
35. Rodriguez D., Rojas-Rivera D., Hetz C. Integrating stress signals at the endoplasmic reticulum: the BCL-2 protein family rheostat. Biochim. Biophys. Acta 2011, 1813:564-574.
36. Rutkowski D.T., Kaufman R.J. A trip to the ER: coping with stress. Trends Cell Biol. 2004, 14:20-28.
37. Seider K., Brunke S., Schild L., Jablonowski N., Wilson D., Majer O., Barz D., Haas A., Kuchler K., Schaller M., Hube B. The facultative intracellular pathogen Candida glabrata subverts macrophage cytokine production and phagolysosome maturation. J. Immunol. 2011, 187:3072-3086.
38. Smith R.P., Baltch A.L., Ritz W.J., Bopp L.H. Comparison of time-kill curves and post-antifungal effects (PAFE) of anidulafungin, caspofungin and micafungin against fluconazole-resistant Candida glabrata and Candida parapsilosis. Diagn. Microbiol. Infect. Dis. 2011, 71:131-138.
39. Smith R.P., Baltch A.L., Ritz W.J., Michelsen P.B., Bopp L.H. IFN-γ enhances killing of methicillin-resistant Staphylococcus aureus by human monocytes more effectively than GM-CSF in the presence of daptomycin and other antibiotics. Cytokine 2010, 51:274-277.
40. Stevens D.A. A possible mechanism for synergy between antifungal therapy and immune defenses. J. Infect. Dis. 2008, 198:159-162.
41. Stevens D.A., Kulberg B.J., Brimmer E., Casadevall A., Netea M.G., Sugar A.M. Combined treatment: antifungal drugs with antibodies, cytokines or drugs. Med. Mycol. 2000, 38(Suppl 1):305-315.
42. Stevens D.L. Immune modulatory effects of antibiotics. Curr. Opin. Infect. Dis. 1996, 9:165-169.
43. Stuart A., Ord J.K. Kendall's advanced theory of statistics 1991, Vol. 2:1138. Oxford University Press, New York, NY, Table 29.8.
44. Stuart A., Ord J.K. Kendall's advanced theory of statistics 1991, Vol. 2:1149. Oxford University Press, New York, NY, Section 29.58.
45. Stuart A., Ord J.K. Kendall's advanced theory of statistics 1991, Vol 2:988. Oxford University Press, New York, NY, Section 26.24.
46. Suffredini A.F., Munford R.S. Novel therapies of septic shock over the past 4 decades. JAMA 2011, 306:194-199.
47. Villamón E., Gozalbo D., Roig P., O'Connor J.E., Fradelizi D., Gil M.L. Toll-like receptor-2 is essential in murine defenses against Candida albicans infections. Microbes Infect. 2004, 6:1-7.
48. Wisplinghoff H., Bischoff T., Tallent S.M., Seifert H., Wenzel R.P., Edmond M.B. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. 2004, 39:309-317.
49. Zaas A.K. Echinocandins: a wealth of choice - how clinically different are they?. Curr. Opin. Infect. Dis. 2008, 21:426-432.